BioNTech, Fosun start Phase II preliminary of COVID-19 vaccine in China

Overview

• Post By : Kumar Jeetendra


• Source: Reuters


• Date: 25 Nov,2020

BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase II clinical trial of BioNTech’s experimental COVID-19 vaccine in China.

The vaccine, known as BNT162b2, will be tested on volunteers at the Jiangsu Provincial Center for Disease Control and Prevention to assess safety and immunogenicity, eyeing future acceptance in China, both firms said in a statement.

BioNTech is also working with U.S. pharma giant Pfizer on the vaccine and the spouses said last week they were expecting to win approval in the United States and Europe this season after trial results revealed the compound had a 95% efficacy rate and caused no serious side effects.